Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy

Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy

Background The main challenge against patients with cancer to derive benefits from immune checkpoint inhibitors targeting PD-1/PD-L1 appears to be the immunosuppressive tumor microenvironment (TME), in which IL-33/ST2 signal fulfills critical functions. However, whether IL-33 limits the therapeutic...

Full description

Bibliographic Details
Main Authors: Yu Bai, Tao Wu, Jun Lin, Shuwen Xu, Xian Zeng, Xuyao Zhang, Jiajun Fan, Dianwen Ju, Mengyang Li, Yanyang Nan, Xiaozhi Hu, Kaicheng Zhou, An Zhu, Zihan Dou, Zhonglian Cao, Xumeng Zhang, Yuanzhen Zhang, Xuebin Wang
Format: Article
Language:English
Published: BMJ Publishing Group 2024-09-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/9/e009236.full

Internet

https://jitc.bmj.com/content/12/9/e009236.full

Similar Items